#Sweden #Stockholm #Nevisense #SciBase #Skin Cancer

Nevisense Technology Recognized in New German Imaging Guidelines

On January 23, 2025, SciBase Holding AB announced that the new German S1 guidelines for imaging have officially recognized Nevisense. This development underscores Nevisense's role in detecting both melanoma and non-melanoma skin cancers while also highlighting its potential applications in managing Atopic Dermatitis (AD).

Nevisense, which employs advanced Electrical Impedance Spectroscopy (EIS) technology, provides dermatologists with a powerful tool for skin cancer diagnosis. The updated guidelines assert that once seborrhoeic keratoses and inflammatory lesions have been clinically or dermatoscopically ruled out, Nevisense stands out as a significant decision-making resource. This recognition is crucial as it is poised to improve patient outcomes by facilitating earlier detection of skin cancers, consequently reducing the number of unnecessary excisions required to diagnose melanoma.

The German S1 guidelines focus extensively on imaging technologies, and the inclusion of Nevisense marks a significant endorsement of its efficacy. According to Pia Renaudin, CEO of SciBase, the guidelines reflect a positive trajectory for the adoption of Nevisense technology in Germany. She noted, "The guidelines have a primary focus on imaging technologies, so it is very positive that they include Nevisense and state that it is a valuable technology in detecting skin cancer. This recognition also opens doors for potential applications in Atopic Dermatitis, which is a developing area for us."

Further updates are anticipated later this year as the S3 guidelines, which will specifically concentrate on melanoma, are set to be released. Nevisense's high sensitivity assists medical professionals in making informed decisions regarding potential cancer interventions. By incorporating Nevisense into standard diagnostic practices, it is expected that there will be less reliance on invasive procedures, improving overall patient experience and reducing healthcare costs.

The path to integrating Nevisense into routine clinical practices illustrates the commitment of SciBase to advance skin health management through technology. Built upon over two decades of research conducted at the renowned Karolinska Institute in Stockholm, Sweden, SciBase aims to enhance diagnostic precision in dermatology. The commitment of the company revolves around minimizing patient suffering, enabling clinicians to improve lives through timely detection and interventions, while also reducing costs for healthcare providers.

The updated guidelines can be accessed in detail on the official German dermatology website here. Moreover, further details about SciBase and their groundbreaking technologies can be found on their website, www.scibase.com.

In conclusion, the acknowledgment of Nevisense in Germany's updated S1 imaging guidelines is a substantial step forward in the fight against skin cancer. It highlights the ongoing advancements in technology within healthcare, illustrating how innovative solutions can lead to better health outcomes for patients. Through persistent research and development, companies like SciBase continue to push boundaries, providing clinicians with the tools necessary for effective and efficient patient care.